Mycophenolate mofetil for ocular myasthenia

Journal of Neurology

Volumn 255, Issue 4, 2008, Pages 510-513

  Chan, J W ^a  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

Mycophenolate mofetil; Ocular myasthenia

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PYRIDOSTIGMINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CYTOPENIA; DIARRHEA; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE DISEASE; FEMALE; FOLLOW UP; HUMAN; INFECTION; MALE; MALIGNANT NEOPLASTIC DISEASE; MYASTHENIA; NAUSEA; PRIORITY JOURNAL; TREATMENT OUTCOME; VOMITING;

ADULT; AUTOANTIBODIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; MYCOPHENOLIC ACID; OCULOMOTOR MUSCLES; PATIENT COMPLIANCE; PREDNISONE; PROSPECTIVE STUDIES; RECEPTORS, CHOLINERGIC; TREATMENT OUTCOME;

EID: 42549155310     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-008-0718-9     Document Type: Article

References (10)

1. Chaudhry V, Cornblath DR, Griffin JW, O'Brien R, Drachman DB (2001) Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 56(1):94-96
2. Meriggioli MN, Ciafaloni E, Al-Hayk KA, Rowin J, Tucker-Lipscomb B, Massey JM, Sanders DB (2003) Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 61(10):1438-1440
3. Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB (2001) Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 56(1):97-99
4. Oosterhuis HJ (1989) The natural course of myasthenia gravis: a long term follow up study. J Neurol Neurosurg Psychiatry 52(10):1121-1127
5. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ,Keesey JC, Penn AS, Sanders DB (2000) Myasthenia gravis: recommendations for clinical research standards Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55(1):16-23
6. Sommer N, Sigg B, Melms A, Weller M, Schepelmann K, Herzau V, Dichgans J (1997) Ocular myasthenia gravis: response to long-term immunosuppressive treatment. J Neurol Neurosurg Psychiatry 62(2):156-162
7. Bever CT Jr, Aquino AV, Penn AS, Lovelace RE, Rowland LP (1983) Prognosis of ocular myasthenia. Ann Neurol 14(5):516-519
8. Vincent A, Newsom-Davis J (1985) Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 48(12):1246-1252
9. Kupersmith MJ (2004) Does early treatment of ocular myasthenia gravis with predisone reduce progression to generalized disease? J Neurol Sci 217(2):123-124
10. Monsul NT, Patwa HS, Knorr AM, Lesser RL, Goldstein JM (2004) The effect of prednisone on the progression from ocular to generalized myasthenia gravis. J Neurol Sci 217(2):131-133